On August 14, 2025 CPTx, a biotechnology company developing in vivo genetic medicines built with programmable single-stranded DNA (ssDNA), reported the QUIET-CAR collaborative project with NanoCell Therapeutics has received a Eurostars Grant from the European Union through the Horizon Europe program and Eureka Network (Press release, CPTx Bio, AUG 14, 2025, View Source [SID1234655419]). The focus of the QUIET-CAR project is development of targeted lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR T therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"CPTx is committed to bringing in vivo CAR T therapies to patients through our proprietary pipeline development programs and now also through the QUIET-CAR project with NanoCell," said Hendrik Dietz, CEO of CPTx. "The QUIET-CAR project represents another innovative approach to CAR T, and we look forward to advancing it together. Being selected from so many high-quality submissions underscores the promise of the project and the strength of our technology."
Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a funding initiative to accelerate transnational innovation. With participation from 37 countries, the program selects only the most promising technological breakthroughs, evaluated by independent experts. The selection of the CPTx – NanoCell project from more than 120 proposals reflects QUIET-CAR’s strong scientific and clinical potential across oncology and autoimmune diseases. NanoCell Therapeutics is a privately held biotechnology company pioneering transformative in vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.